Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Blood (2024) 144 (Supplement 1): 4698.

https://doi.org/10.1182/blood-2024-205164

Published: 2024

Journal Articles

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

Blood (2024) 144 (Supplement 1): 1636.

https://doi.org/10.1182/blood-2024-202823

Published: 2024

Journal Articles

Phase II Study of Lenalidomide Maintenance after Salvage Therapy for Relapsed or Refractory Peripheral T-Cell Lymphomas

Seok Jin Kim, Myung-Won Lee, Sung-Nam Lim, Ka-Won Kang, Sang Eun Yoon, Yoo Jin Lee, Hye Jin Kang, Ho Sup Lee, Hyo Jung Kim, Hong Hoe Koo, Ho-Jin Shin, Hyeon-Seok Eom, Jong-Ho Won, Won Seog Kim

Blood (2023) 142 (Supplement 1): 3073.

https://doi.org/10.1182/blood-2023-181809

Published: 2023

Journal Articles

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Blood (2023) 142 (Supplement 1): 6638.

https://doi.org/10.1182/blood-2023-183100

Published: 2023

Journal Articles

Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Noriko Fukuhara, Won Seog Kim, Dok Hyun Yoon, Eiju Negoro, Kazuhito Yamamoto, Toshiki Uchida, Koji Izutsu, Yasuhito Terui, Hideaki Nakajima, Kiyoshi Ando, Youko Suehiro, Hye Jin Kang, Po-Shen Ko, Fumiko Nagahama, Yusuke Sonehara, Hirokazu Nagai, Hwei-Fang Tien, Yok-Lam Kwong, Kensei Tobinai

Blood (2021) 138 (Supplement 1): 1376.

https://doi.org/10.1182/blood-2021-145512

Published: 2021

Journal Articles

Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

Blood (2019) 134 (Supplement_1): 2844.

https://doi.org/10.1182/blood-2019-129664

Published: 2019

Journal Articles

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

Jae-Cheol Jo, MD, Ho Sup Lee, MD, Cheolwon Suh, Hye Jin Kang, MD PhD, Won Seog Kim, MD PhD, HyeonSeok Eom, MD PhD, Inho Kim, MD PhD, Ho-Jin Shin, MD PhD, Yong Park, Won Sik Lee, MD PhD, Young Rok Do, PhDMD, Lee Gyeong-Won, Sung Yong Oh, Sung-Nam Lim, MD, Seong Yoon Lee, MD

Blood (2019) 134 (Supplement_1): 2884.

https://doi.org/10.1182/blood-2019-132192

Published: 2019

Journal Articles

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Blood (2019) 134 (Supplement_1): 4035.

https://doi.org/10.1182/blood-2019-126637

Published: 2019

Journal Articles

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Ho Sup Lee, MD PhD, Chang-Ki Min, MD PhD, Kihyun Kim, MD, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Sung-Soo Yoon, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, MD PhD, Dok Hyun Yoon, MD PhD, Cheolwon Suh, Ho-Jin Shin, MD PhD, Yeung-Chul Mun, MD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, Hye Jin Kang, MD PhD

Blood (2019) 134 (Supplement_1): 3114.

https://doi.org/10.1182/blood-2019-122404

Published: 2019

Journal Articles

Autologous EBV-Specific T Cells (CMD-003): Early Results from a Multicenter, Multinational Phase 2 Trial for Treatment of EBV-Associated NK/T-Cell Lymphoma

Blood (2017) 130 (Supplement 1): 4073.

https://doi.org/10.1182/blood.V130.Suppl_1.4073.4073

Published: 2017

Journal Articles

A Phase II Study of Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma

Silvia Park, Seok Jin Kim, MD PhD, Jung Yong Hong, Dok Hyun Yoon, MD PhD, Jin Seok Kim, MD PhD, Hye Jin Kang, MD PhD, Hyeon-Seok Eom, Mark Hong Lee, Cheolwon Suh, MD PhD, Won Seog Kim, MD, Ph. D.

Blood (2017) 130 (Supplement 1): 4077.

https://doi.org/10.1182/blood.V130.Suppl_1.4077.4077

Published: 2017

Journal Articles

A Prospective Registry Study of Peg-G-CSF Prophylaxis for Patients with Diffuse Large B-Cell Lymphoma (CISL 1403)

Blood (2017) 130 (Supplement 1): 2840.

https://doi.org/10.1182/blood.V130.Suppl_1.2840.2840

Published: 2017

Journal Articles

the Safety and Efficacy of Pomalidomide in Combination with Cyclophosphamide and Dexamethasone (PCD) in the Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma (MM) Who Had Lenalidomide Plus Dexamethasone (LD) Following Frontline Bortezomib Combined Chemotherapy, Open-Labeled, Multicenter Phase II Study

Ho Sup Lee, MD, Chang-Ki Min, MD PhD, Kihyun Kim, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, Dok Hyun Yoon, MD PhD, Cheolwon Suh, MD PhD, Ho-Jin Shin, MD, Yeung-Chul Mun, MD PhD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, MD PhD, Hye Jin Kang, MD PhD, Sung-Soo Yoon, MD PhD

Blood (2017) 130 (Supplement 1): 1834.

https://doi.org/10.1182/blood.V130.Suppl_1.1834.1834

Published: 2017

Journal Articles

Unmet Needs for a Better Treatment in Patients with Peripheral T Cell Lymphoma: Data from a Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

Blood (2017) 130 (Supplement 1): 4088.

https://doi.org/10.1182/blood.V130.Suppl_1.4088.4088

Published: 2017

Journal Articles

The Efficacy of JAK2 Inhibitor in Heavily Pretreated Classical Hodgkin Lymphoma: A Prospective Pilot Study of Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma

Seok Jin Kim, MD PhD, Hye Jin Kang, MD PhD, Shin Dong-Yeop, MD PhD, Ho Sup Lee, Sung Yong Oh, MD, Ho-Jin Shin, MD PhD, Dok Hyun Yoon, Jung Yong Hong, MD, Jee Hyun Kong, Kana Sakamoto, Young Hyeh Ko, MD, Kengo Takeuchi, MD PhD, Cheolwon Suh, Won Seog Kim

Blood (2016) 128 (22): 1820.

https://doi.org/10.1182/blood.V128.22.1820.1820

Published: 2016

Journal Articles

Randomized Phase II Multi-Center Trial of Busulfan, Etoposide, and Cyclophosphamide Versus Busulfan, Etoposide, and Melphalan As Conditioning Therapy for Autologous Transplantation in Patients with Non-Hodgkin's Lymphoma: A Multicenter Study from Consortium for Improving Survival of Lymphoma (CISL)

Kyoung Ha Kim, Lee Jae Hoon, Mark Lee, Kim Hoon-Gu, Young Rok Do, Yong Park, MD PhD, Sung Yong Oh, MD, Ho-Jin Shin, MD PhD, Won Seog Kim, Sung-Kyu Park, MD, Jong-Ho Won, Jee Hyun Kong, Moo-Rim Park, MD, Je-Jung Lee, Jae-Yong Kwak, Hye Jin Kang, MD PhD, Yeung-Chul Mun

Blood (2016) 128 (22): 3466.

https://doi.org/10.1182/blood.V128.22.3466.3466

Published: 2016

Journal Articles

Bortezomib-Melphalan-Prednisone (VMP) Versus MP As Initial Treatment for Patients Older Than 75 Years with Newly Diagnosed Multiple Myeloma

Min Kyoung Kim, MD, Kihyun Kim, MD PhD, Dok Hyun Yoon, Cheolwon Suh, Jae Hoon Lee, MD, Sung-Hoon Jung, Je-Jung Lee, Hyo Jung Kim, Jin Seok Kim, Jeong-Ok Lee, Hyeon Seok Eom, MD PhD, Won Sik Lee, MD, Yeung-Chul Mun, Young Rok Do, Hye Jin Kang

Blood (2016) 128 (22): 5683.

https://doi.org/10.1182/blood.V128.22.5683.5683

Published: 2016

Journal Articles

Clinical Outcomes in Patients with Diffuse Large B Cell Lymphoma with Partial Responses to First-Line R-CHOP Chemotherapy: Prognostic Value of Secondary IPI Scores and FDG-PET

Hyewon Lee, MD, Yu Ri Kim, Soo-Jeong Kim, MD, Yong Park, MD PhD, Hyeon-Seok Eom, Sung Yong Oh, MD, Hyo Jung Kim, Hye Jin Kang, Won-Sik Lee, Joon Ho Moon, MD, PhD, Young-Woong Won, MD PhD, Myung Hee Chang, Hye In Park, Jin Seok Kim, MD PhD

Blood (2016) 128 (22): 4205.

https://doi.org/10.1182/blood.V128.22.4205.4205

Published: 2016

Journal Articles

Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma

Seok Jin Kim, MD PhD, Hye Jin Kang, MD PhD, Dong-Yeop Shin, MD, Dok Hyun Yoon, Kana Sakamoto, MD, Jee Hyun Kong, MD, Young Hyeh Ko, MD PhD, Kengo Takeuchi, MD PhD, Cheolwon Suh, MD, PhD, Won Seog Kim, MD PhD

Blood (2014) 124 (21): 4443.

https://doi.org/10.1182/blood.V124.21.4443.4443

Published: 2014

Journal Articles

Clinical Outcomes of R-CHOP Chemotherapy Alone Compared with R-CHOP Plus Radiotherapy in Patients with Localized, Non-Bulky Diffuse Large B-Cell Lymphoma

Blood (2014) 124 (21): 4421.

https://doi.org/10.1182/blood.V124.21.4421.4421

Published: 2014

NARROW

Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

Phase II Study of Lenalidomide Maintenance after Salvage Therapy for Relapsed or Refractory Peripheral T-Cell Lymphomas

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Autologous EBV-Specific T Cells (CMD-003): Early Results from a Multicenter, Multinational Phase 2 Trial for Treatment of EBV-Associated NK/T-Cell Lymphoma

A Phase II Study of Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma

A Prospective Registry Study of Peg-G-CSF Prophylaxis for Patients with Diffuse Large B-Cell Lymphoma (CISL 1403)

Unmet Needs for a Better Treatment in Patients with Peripheral T Cell Lymphoma: Data from a Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

The Efficacy of JAK2 Inhibitor in Heavily Pretreated Classical Hodgkin Lymphoma: A Prospective Pilot Study of Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma

Randomized Phase II Multi-Center Trial of Busulfan, Etoposide, and Cyclophosphamide Versus Busulfan, Etoposide, and Melphalan As Conditioning Therapy for Autologous Transplantation in Patients with Non-Hodgkin's Lymphoma: A Multicenter Study from Consortium for Improving Survival of Lymphoma (CISL)

Bortezomib-Melphalan-Prednisone (VMP) Versus MP As Initial Treatment for Patients Older Than 75 Years with Newly Diagnosed Multiple Myeloma

Clinical Outcomes in Patients with Diffuse Large B Cell Lymphoma with Partial Responses to First-Line R-CHOP Chemotherapy: Prognostic Value of Secondary IPI Scores and FDG-PET

Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma

Clinical Outcomes of R-CHOP Chemotherapy Alone Compared with R-CHOP Plus Radiotherapy in Patients with Localized, Non-Bulky Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only